BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

"At Mayo Clinic, we think that delivering intravesical therapy for non-muscle invasive bladder cancer in patients' homes has the potential to reduce treatment burden, improve the patient experience, ...

The submission of this innovative intravesical drug releasing system is supported by data from the Phase 2b ... In December 2023, the FDA granted Breakthrough Therapy Designation (BTD) to TAR-200 for ...

If approved, TAR-200 will be the first intravesical drug-releasing system ... Although primarily used to prevent tuberculosis, the BCG vaccine is also a standard treatment for some forms of ...

However, the Merck and ImmunityBio drugs utilize a different mechanism of action — IBRX’s Anktiva is an IL-15 antibody drug, approved for intravesical use in combination with the BCG vaccine.

India is emerging as a leader in artificial intelligence (AI) investment and adoption, according to the latest AI Radarton Consulting Group (BCG) report from Bos. This report reveals that 80% of ...

The filing seeks approval for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

BCG unresponsive non-muscle invasive bladder cancer (NMIBC) in the papillary indication: Anticipated supplemental biologics license application (BLA) submission in 2025 Alternative source of BCG ...